11.12.2012 Views

continued from part 1 - Controller General of Patents, Designs, and ...

continued from part 1 - Controller General of Patents, Designs, and ...

continued from part 1 - Controller General of Patents, Designs, and ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

(12) PATENT APPLICATION PUBLICATION (21) Application No.6200/DELNP/2008 A<br />

(19) INDIA<br />

(22) Date <strong>of</strong> filing <strong>of</strong> Application :16/07/2008 (43) Publication Date : 24/10/2008<br />

(54) Title <strong>of</strong> the invention : "IMPROVED METHOD FOR EXPANSION OF TUMOUR -REACTIVE T-LYMPHOCYTES FOR<br />

IMMUNOTHERAPY OF PATIENTS WITH CANCER"<br />

(51) International classification :C12N 5/06 (71)Name <strong>of</strong> Applicant :<br />

(31) Priority Document No :60/752, 828<br />

1)SENTOCLONE AB<br />

(32) Priority Date :21/12/2005<br />

Address <strong>of</strong> Applicant :ALLEN 5, SE-17266 SUNDBYBERG,<br />

(33) Name <strong>of</strong> priority country :U.S.A.<br />

SWEDEN. Sweden<br />

(86) International Application No :PCT/EP2006/012304 (72)Name <strong>of</strong> Inventor :<br />

Filing Date<br />

:20/12/2006<br />

1)OLA WINQVIST<br />

(87) International Publication No :WO 2007/071388 2)MAGNUS THORN<br />

(61) Patent <strong>of</strong> Addition to Application<br />

Number<br />

Filing Date<br />

:NA<br />

:NA<br />

(62) Divisional to Application Number :NA<br />

Filing Date<br />

:NA<br />

(57) Abstract :<br />

The present invention discloses an improved method for expansion <strong>and</strong> activation <strong>of</strong> tumour-reactive lymphocytes, in <strong>part</strong>icular CD4+<br />

helper <strong>and</strong>/or CD8+ T-lymphocytes, which may be used for treating <strong>and</strong>/or preventing cancer. The method provides high numbers <strong>of</strong><br />

tumour-reactive T-lymphocytes within a short time span <strong>and</strong> the possibility <strong>of</strong> directing development <strong>of</strong> tumour-reactive CD4+ helper<br />

<strong>and</strong>/or CD8+ T-lymphocytes towards specific subpopulations. The method comprises a first phase <strong>of</strong> stimulating tumour-reactive<br />

CD4+ T helper <strong>and</strong>/or CD8+ T-lymphocytes with tumour-derived antigen together with at least one substance having agonistic<br />

activity towards the IL-2 receptor to promote survival <strong>of</strong> tumour-reactive CD4+ T helper <strong>and</strong>/or CD8+ T-lymphocytes; <strong>and</strong> a second<br />

phase <strong>of</strong> activating <strong>and</strong> promoting growth <strong>of</strong> tumour-reactive CD4+ T helper <strong>and</strong>/or CD8+ T-lymphocytes, wherein the second phase<br />

is initiated when the CD25 cell surface marker (or IL-2R marker) is down-regulated on CD4+ T helper <strong>and</strong>/or CD8+ T-lymphocytes.<br />

No. <strong>of</strong> Pages : 61 No. <strong>of</strong> Claims : 21<br />

The Patent Office Journal 24/10/2008 25746

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!